MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate ulcerative colitis (UC).Press Release
MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, outlined the proprietary technology of the company at the 5th Microbiome Movement - Drug Development Summit Europe 2021.
The presentation, entitled “MRM Health – the Next Level in Optimized Consortia Development”, outlined the company’s innovative and unique approach in developing and manufacturing Optimized Synthetic Consortia as well as its pipeline.Press Release
Microbiome specialist MRM Health is pleased to announce the appointment of its Chairman of the Board and its Chief Scientific Officer.
MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, announced today that Dr. Werner Cautreels, former CEO of Solvay Pharmaceuticals and Selecta Biosciences, has been appointed as Chairman of the Board and Dr. Nigel Horscroft, ex-Curevac and Pfizer, as Chief Scientific Officer. In addition, Dr. Ludo Haazen is joining the R&D organization to support clinical development and medical affairs.Press Release
Microbiome specialist MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences in the field of metabolic diseases. Furthermore, MRM Health has raised more than €14 million to advance its in-house clinical and preclinical development programs in the field of microbiome-based therapeutics and strengthens its partnership with the Flemish Institute of Biotechnology (VIB), KU Leuven and Ghent University.Press Release